Navigation Links
Multiple Vimpat(R) (lacosamide) Studies Presented at American Epilepsy Society Annual Meeting
Date:12/8/2008

9 percent for placebo) and also for median increase in percentage of seizure-free days (7.4 percent, 9.3 percent, and 12.1 percent vs. 5.4 percent for placebo) for those entering the maintenance period.

The pooled results among all patients in the intent-to-treat analysis, including those who dropped out during the titration period, also demonstrated statistically significant reductions in seizure frequency at all doses studied compared to placebo:

-- Seizure frequency was reduced by 33.3 percent for the 200 mg/day group, 36.8 percent for the 400 mg/day group, and by 39.4 percent for the 600 mg/day group, compared with 18.4 percent for placebo (p<.05 for the 200 mg/day group and p<.0001 for the 400 and 600 mg/day groups vs. placebo).

-- Responder rates were 34.1 percent for 200 mg/day, 39.7 percent for 400 mg/day, and 39.6 percent for 600 mg/day, compared with 22.6 percent for placebo (p<.05 for the 200 mg/day group and p<.0001 for the 400 and 600 mg/day groups vs. placebo).

Poster Session 3, December 8, 2008, 8:00 - 9:00 am (Poster 3.196)

Steve Chung, MD, David Rudd, David Hebert, PhD, Pamela Doty

Barrow Neurological Institute, Phoenix, AZ; SCHWARZ BIOSCIENCES (a member of the UCB Group), Research Triangle Park, Raleigh, North Carolina

Lacosamide Efficacy is Independent of Concomitant AED(s) Treatment

This analysis evaluated pooled data from the placebo and 400 mg/day Vimpat(R) treatment groups of each trial by the most frequently used concomitant AEDs. The most commonly used concomitant AEDs for this patient population were carbamazepine, lamotrigine, levetiracetam, valproate, and oxcarbazepine.

Overall, reduction in seizure frequency was 36.8 percent for adjunctive treatment with Vimpat(R) 400 mg/day versus 18.4 percent for adjunctive treatment with placebo. When analyzed by individual concomitant AED use, Vimpa
'/>"/>

SOURCE UCB
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Genomic Health to Present Multiple New Studies at 31st Annual San Antonio Breast Cancer Symposium
2. Derma Sciences Announces Multiple Clinical Posters Featuring MEDIHONEY(R) and ALGICELL Ag(R) to be Presented at Upcoming Wound Care Conference
3. TorreyPines Therapeutics Begins Dosing in a Phase I Multiple Dose Clinical Trial of NGX426, Oral Prodrug of Tezampanel
4. Senescos Preclinical Multiple Myeloma Data to be Presented at the 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
5. Bolder BioTechnology Receives $1.6 million NIH Grant to Continue Development of Multiple Sclerosis Drug
6. Environmental Tectonics Corporation Announces a Multiple Sale of Hyperbaric Monoplace Chambers to Comprehensive Healthcare Solutions
7. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
9. Orexigen Therapeutics Announces Multiple Data Presentations at The Obesity Society Annual Scientific Meeting
10. Memory Pharmaceuticals Completes Phase 1 Multiple Ascending Dose Study of R4996/MEM 63908
11. Environmental Tectonics Corporation Announces a Multiple Sale for Monoplace Hyperbaric Chambers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... MN (PRWEB) , ... July 31, 2015 , ... Ralco ... Enrichment Center at the Lyon County Fair to be held August 5-9 in Marshall. ... about where their meals come from and how agriculture impacts their daily lives. This ...
(Date:7/30/2015)... July 30, 2015 According to ... (Software, Molecular Modeling, PB/PK, PKPD, Trial Design, Toxicity Prediction, ... Preclinical, Clinical Trial), by End Users - Global Forecast ... expected to reach USD 2,107.99 million by 2020 from ... 15.29%. Browse more than ...
(Date:7/30/2015)... Ascendis Pharma A/S (Nasdaq: ASND ... TransCon technology to address significant unmet medical needs, ... Phase 2 study to evaluate the safety and ... treatment-naïve, pre-pubertal children with growth hormone deficiency, or ... the top-line results from our Phase 2 pediatric ...
(Date:7/29/2015)... July 30, 2015 Sanofi, ... for the second quarter of 2015. CEO ... and its performance in different businesses. ... http://www.eurobusinessmedia.com/ceo-direct/sanofi/sanofi-h1-2015-results-interview-with-ceo-olivier-brandicourt?utm_source=ceo-direct&utm_medium=wire Topics covered in ... - Performance drivers - ...
Breaking Biology Technology:Ralco Announces Primary Sponsorship of Ralco Enrichment Center at Lyon County Fair 2Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7
... a privately-held company focused on advancing women,s reproductive health, today ... A financing, bringing the total funding to $20 million. The ... the round include Kleiner Perkins Caufield and Byers, TPG Biotech ... the last year, we have executed an aggressive operating plan ...
... 2012   Reportlinker.com announces that a new market ... U.S. Tissue Engineering Markets ... The scope of this research service primarily ... the wound care and surgery space. Surgery ...
... Feb. 1, 2012 Sangamo BioSciences, Inc. (Nasdaq: ... fourth quarter and full year 2011 financial results on Wednesday, ... will be followed by a conference call at 5:00 p.m. ... and webcast. During the conference call, the company will review ...
Cached Biology Technology:Auxogyn Completes $20 Million In Series A Funding 2Auxogyn Completes $20 Million In Series A Funding 3U.S. Tissue Engineering Markets 2U.S. Tissue Engineering Markets 3Sangamo BioSciences Announces Fourth Quarter and Full Year 2011 Conference Call and Webcast 2
(Date:7/31/2015)... , Kina, 31. juli 2015 Den 10. ... afholdt af BGI fra den 22. - 25. oktober i ... Konferencen fejrer sin 10-års fødselsdag i år. Siden starten ... indflydelsesrige årlige møder på ,omik,-feltet, og er en af ... ICG-10 fokuserer på nylige gennembrud og fremskridt ...
(Date:7/31/2015)... julio de 2015 BGI llevará a cabo la ... 22 al 25 de octubre de 2015, en ... celebra su décimo aniversario este año. Desde su inauguración ... las reuniones anuales más influyentes del mundo en los ... conferencias científicas más dinámicas, entusiastas y amenas. ...
(Date:7/31/2015)... , 31 de julho de 2015 ... www.icg-10.org ) será realizada pela BGI de 22-25 de ... . A conferência está celebrando seu 10 ... 2006, a ICG se tornou uma das reuniões mais ... dos encontros científicos mais dinâmicos, entusiastas e prazerosos. ...
Breaking Biology News(10 mins):Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3
... a new way of looking beneath the ocean surface ... shrinking. , A remote sensor system developed by Associate ... at MIT, Northeastern University and the Naval Research Laboratory, ... as well as small schools, over a 10,000-square-kilometer area ...
... of Pennsylvania, demonstrate that biodegradable nano-particles containing two ... breast tumors. The unique properties of the ... to deliver two distinct drugs, paclitaxel, the leading ... Taxol, and doxorubicin directly to tumors implanted in ...
... have found a way to keep a protein "watchdog" on ... - if they can keep it on a leash of ... team of scientists including Purdue University's Susan M. Mendrysa has ... has the ability to halt the progression of intestinal tumors ...
Cached Biology News:One fish, two fish: New MIT sensor improves fish counts 2Nano-particles effective in killing cancer with one-two punch of chemotherapeutics 2Loosen leash on cancer protein 'watchdog,' researchers say 2Loosen leash on cancer protein 'watchdog,' researchers say 3Loosen leash on cancer protein 'watchdog,' researchers say 4
IEX-1 S/L (H-20)...
Mouse monoclonal [1.T.4] to WAVE 1 ( Abpromise for all tested applications). Antigen: His6 fusion protein corresponding to full-length rat WAVE1. Entrez Gene ID: 8936...
For the differentiation of mouse embryonic stem cells tooligodendrocytes....
VAP-1 (S-13)...
Biology Products: